Clinical Trial Update: JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies [NA]

View source ↗

Summary

A clinical trial update indicates JY231 injection is being studied for relapsed/refractory B-cell malignancies and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• JY231

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: B-cell Malignancies | NA | Status: RECRUITING